查詢結果分析
相關文獻
- 阿茲海默症簡介
- 阿茲海默症藥物治療準則
- 阿茲海默症的新展望
- Metrifonate--一種治療阿茲海默症(Alzheimer's disease, AD)的新藥
- Donepezil(Aricept[feb9])--治療阿茲海默症的新藥
- Efficiency, Capacity, and Implicit Learning: An Account of the Effects of Aging and Alzheimer's Disease on the Performance in Sequence Learning
- 失智症患者的語言表現和治療
- 阿茲海默症之新進研究與未來展望
- 阿茲海默症用乙醯膽鹼酶抑制劑治療之爭議
- 阿茲海默症的主嫌犯--類澱粉蛋白β的危害
頁籤選單縮合
題名 | 阿茲海默症簡介=Introduction of Alzheimer's Disease |
---|---|
作者姓名(中文) | 沈郁芳; | 書刊名 | 藥學雜誌 |
卷期 | 28:2=111 2012.06[民101.06] |
頁次 | 頁99-104 |
分類號 | 415.8471 |
關鍵詞 | 阿茲海默症; BACE抑制劑; Aβ免疫療法; 早老素; CHE抑制劑; NMDA接受體拮抗劑; |
語文 | 中文(Chinese) |
中文摘要 | 目前全球大約有二千六百萬人口罹患阿茲海默症,在台灣大約也有六萬人左右受此病症的困擾。其主要病徵包含記憶喪失、無法操作熟悉事物、說重複的話、判斷力異常、睡眠障礙、情緒及行為改變。大多數的文獻報告顯示,它可能涉及複雜的病理路徑如:腦內膽鹼物質分泌量減少、麩胺酸毒殺神經細胞、β 澱粉樣蛋白 (beta-amyloids protein, Aβ) 沉積、基因結構改變等假說論。到目前為止臨床上尚未有根治的方法。不過,近年來,許多藥廠或各國研究團隊,正積極研發抗阿茲海默症的 BACE (β-site amyloid precursor protein eleaving enzyme) 抑制劑與 β 澱粉樣蛋白 (Aβ) 免疫療法,期盼不久的將來,新治療藥上市後能夠有效地預防或根治阿茲海默症。 |
英文摘要 | Alzheimer's disease (AD) is one of the most common type of dementia. As the average lifespan increases worldwide, the number of AD patients will continue to rise. Many scholars believe that AD is a multifactorial syndrome with degeneration of the neurons, abnormal activity of metabotropic glutamate receptors, beta-amyloids protein deposition and genetic determinants triggering the pathological decline. A large number of studies have been made on AD, however, the problem is still controversial. Today, several drugs provide modest improvements in the memory and cognition problems caused by AD. These patients benefit from nutritional support and lifestyle enhancement encouraged through medical professionals' primary care, but treatments of AD is difficult. In recent years, some new human clinical trials for both BACE inhibitors and Aβ immunotherapy are underway. We are hopeful new therapies will succeed in preventing and treating AD. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。